Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2016

Open Access 01-12-2016 | Case report

Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report

Authors: Katharina Schroeder, Tobias Meyer-ter-Vehn, Heidi Fassnacht-Riederle, Rainer Guthoff

Published in: Journal of Medical Case Reports | Issue 1/2016

Login to get access

Abstract

Background

Multifocal choroiditis with panuveitis is a rare disease. The educational merit of this case presentation results from the good documentation and the impressive ocular fundus pictures.

Case presentation

We illustrate the 3-year course of disease in a 22-year-old myopic white woman with multifocal choroiditis with panuveitis and secondary choroidal neovascularization. The activity of the disease was evaluated clinically by optical coherence tomography and fluorescein angiography. Choroidal neovascularization was treated by intravitreal bevacizumab (2.5 mg/0.1 ml). Our patient lacked systemic therapy for the first 11 months because of noncompliance.

Conclusions

The case is remarkable as the delayed onset of peripheral lesions and the additional existence of high myopia made diagnosis difficult. In addition, it demonstrates that full outbreak of disease with multiple central and peripheral fundus lesions and secondary choroidal neovascularization can develop without systemic treatment.
Literature
2.
go back to reference Fung AT, et al. Multifocal choroiditis without panuveitis: clinical characteristics and progression. Retina. 2014;34:98–107.CrossRefPubMed Fung AT, et al. Multifocal choroiditis without panuveitis: clinical characteristics and progression. Retina. 2014;34:98–107.CrossRefPubMed
3.
go back to reference Fine H, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.CrossRefPubMed Fine H, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.CrossRefPubMed
4.
go back to reference Parodi M, et al. Intravitreal bevacizumab for juxtafoveal choroidal neovascularisation secondary to multifocal choroiditis. Retina. 2013;33:953–6.CrossRefPubMed Parodi M, et al. Intravitreal bevacizumab for juxtafoveal choroidal neovascularisation secondary to multifocal choroiditis. Retina. 2013;33:953–6.CrossRefPubMed
5.
go back to reference Winterhalter S, et al. Inflammatorische choroidale Neovaskularisationen. Klin Monatsbl Augenheilkunde. 2012;229:897–904.CrossRef Winterhalter S, et al. Inflammatorische choroidale Neovaskularisationen. Klin Monatsbl Augenheilkunde. 2012;229:897–904.CrossRef
6.
go back to reference Mansour A, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012;47(3):269–74.CrossRefPubMed Mansour A, et al. Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol. 2012;47(3):269–74.CrossRefPubMed
7.
go back to reference Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33(7):1315–24.CrossRefPubMed Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33(7):1315–24.CrossRefPubMed
9.
go back to reference Troutbeck R, et al. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clin Exp Ophthalmol. 2012;40:60–72.CrossRef Troutbeck R, et al. Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. Clin Exp Ophthalmol. 2012;40:60–72.CrossRef
10.
go back to reference Parodi M, et al. Bevacizumab vs. photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.CrossRefPubMed Parodi M, et al. Bevacizumab vs. photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.CrossRefPubMed
Metadata
Title
Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report
Authors
Katharina Schroeder
Tobias Meyer-ter-Vehn
Heidi Fassnacht-Riederle
Rainer Guthoff
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2016
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-016-1069-2

Other articles of this Issue 1/2016

Journal of Medical Case Reports 1/2016 Go to the issue